Risperidone versus olanzapine for the treatment of delirium
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: This study compared the effectiveness of risperidone and olanzapine in the treatment of delirium. Methods: This was a 7‐day, randomized, comparative clinical trial of risperidone and olanzapine in patients with delirium. The primary outcome measure was the Delirium Rating Scale‐Revised‐98 (DRS‐R‐98). Results: We enrolled 32 subjects (median age, 70 years). Significant within‐group improvements in the DRS‐R‐98 scores over time were observed at every time point in both treatment groups; however, differences in the change of the DRS‐R‐98 score from baseline were not significant between the treatment groups. On the first day after drug treatment, there was a trend toward greater improvement in the DRS‐R‐98 score in the olanzapine group compared with the risperidone group, but it did not reach statistical significance (p = 0.076). The response rates did not differ significantly between the two groups (risperidone group: 64.7%, olanzapine group: 73.3%). However, the response to risperidone was significantly poorer in patients ≥70 years of age compared with those aged <70 years. There was no significant difference in the safety profiles, including extrapyramidal symptoms (EPSs), between the two groups. Conclusion: Risperidone and olanzapine were equally effective in reducing delirium symptoms. The response to risperidone was poorer in the older age group. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delirium as a Predictor of Mortality in Mechanically Ventilated Patients in the Intensive Care Unit
Ely, E. W. (2004) · JAMA · doi:10.1001/jama.291.14.1753 · Cited by 3,073
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · cited 1×
“Safety measures included reported adverse events and EPSs, evaluated based on UKU (Lingjaerde et al., 1987) neurological side effect items (dystonia, rigidity, bradykinesia, tremor, and akathisia).”
MethodSchneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“Furthermore, several studies have reported an increased mortality risk mainly due to cardiovascular disease in elderly dementia patients taking antipsychotics (Schneider et al., 2005).”
Background
Cited by
Neufeld, K. J., Yue, J., Robinson, T. N., Inouye, S. K., & Needham, D. M. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14076 · Cited by 505
Agar, M. R., Lawlor, P. G., Quinn, S., Draper, B., Caplan, G. A., Rowett, D., Sanderson, C., Hardy, J., Le, B., Eckermann, S., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.7491 · Cited by 344
Maldonado, J. R. (2017) · Critical Care Clinics · doi:10.1016/j.ccc.2017.03.013 · Cited by 325
Antipsychotics for Treating Delirium in Hospitalized Adults: A Systematic Review
Nikooie, R., Neufeld, K. J., Oh, E. S., Wilson, L. M., Zhang, A., Robinson, K. A., & Needham, D. M. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1860 · Cited by 246
Antipsychotics for treatment of delirium in hospitalised non-ICU patients
Burry, L., Mehta, S., Perreault, M. M., Luxenberg, J. S., Siddiqi, N., Hutton, B., Fergusson, D. A., Bell, C., & Rose, L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005594.pub3 · Cited by 237
“We excluded five additional studies (Jung 2009; Jung 2010; Kim 2010; Lee 2005; Sakong 2010) because of lack of adequate comparator group.”
Background
Metadata
- Authors
- Kim, S., Yoo, J., Lee, S., Kim, S., Bae, K., Yang, S., Kim, J., Shin, I., & Yoon, J.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2010-05-28
- Volume
- 25
- Issue
- 4
- Pages
- 298-302
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2103120487
- Cited by
- 90
- References
- 3
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.